WaveMan
WaveMan · Company
BEAM · Beam Therapeutics Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BEAM Beam Therapeutics (BEAM) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001745999
Quote by TradingView
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
153
13F, latest reported quarter
Conversions, 180 days
7
Codes C/M, not in net · $130.5K priced

What the filings say about BEAM

Insiders, 180 days
-$13.4M net sold
4 sellers · 27% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.2M
2 notices

Beam Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Beam Therapeutics Inc. insiders sold a net $13.4M of stock across 198 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Evans John M.
CEO
SELL
2026-10-16 SEC
25,000
$599.6K
+2.9%
Context
  • 91 earlier Form 4 trades (code P or S) here by this insider (91 sales), the last on Oct 15, 2026.
  • The trade is 2.4% of the 1,047,205 shares held after it.
  • 1 other insider sold within 30 days.
  • 153 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Evans John M. sold about $599.6K of BEAM under a 10b5-1 plan on Oct 16, 2026; 1 other insider sold within 30 days and 153 funds added in the latest 13F quarter.
Evans John M.
CEO
SELL
2026-10-16 SECtraded 2026-10-15
25,000
$589.1K
+2.9%
Context
  • 90 earlier Form 4 trades (code P or S) here by this insider (90 sales), the last on Jun 30, 2026.
  • The trade is 2.4% of the 1,047,205 shares held after it.
  • 1 other insider sold within 30 days.
  • 153 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Evans John M. sold about $589.1K of BEAM under a 10b5-1 plan on Oct 15, 2026; 1 other insider sold within 30 days and 153 funds added in the latest 13F quarter.
Cavanagh Bethany J
SVP, Finance and Treasurer
SELL
2026-10-02 SECtraded 2026-10-01
187
$4.6K
-3.0%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Apr 1, 2026.
  • The trade is 0.4% of the 50,984 shares held after it.
  • 1 other insider sold within 30 days.
  • 153 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Finance and Treasurer Cavanagh Bethany J sold about $4.6K of BEAM under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 153 funds added in the latest 13F quarter.
Simon Amy
Chief Medical Officer
SELL
2026-07-29 SECtraded 2026-07-27
16,667
$429.0K
-6.0%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Jun 30, 2026.
  • The trade is 19.4% of the 85,696 shares held after it.
  • 1 other insider sold within 30 days.
  • 153 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Simon Amy sold about $429.0K of BEAM on Jul 27, 2026; 1 other insider sold within 30 days and 153 funds added in the latest 13F quarter.
Simon Amy
Chief Medical Officer
SELL
2026-07-02 SECtraded 2026-06-30
373
$13.0K
-29.5%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Apr 1, 2026.
  • The trade is 0.4% of the 102,363 shares held after it.
  • 2 other insiders sold within 30 days.
  • 153 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Simon Amy sold about $13.0K of BEAM on Jun 30, 2026; 2 other insiders sold within 30 days and 153 funds added in the latest 13F quarter.
198 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 193 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$13.4M over 180 days
-$1.2M over 90 days · -$10.0M of it by a 10%+ holder
below 87% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
153 funds bought in last quarter
more than 83% of Pharma & Biotech
Revenue
+120.0% year over year
more than 86% of Pharma & Biotech
Margin
-57.2% net margin
below 52% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
31.2% of the float short (float per yahoo 2026-10-26) · 15.3 days to cover · settled 2026-09-30
more than 98% of Pharma & Biotech
What changed in the last 30 days
Oct 16CEO Evans John M. sold $1.2M under a 10b5-1 plan (2 trades, Oct 15 to Oct 16)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 16Officer JOHN M EVANS filed to sell $599.6K by Oct 16 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 15Officer JOHN M EVANS filed to sell $589.1K by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 2SVP, Finance and Treasurer Cavanagh Bethany J sold $4.6K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.

Watch BEAM

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-11.7%12M
-27%-6%+14%+34%2025-102025-122026-022026-042026-062026-082026-10 2026-06-26 · FMR LLC sold $8.9M2026-06-25 · FMR LLC sold $1.2M2026-02-24 · Ciaramella Giuseppe sold $1.1M2026-06-30 · Evans John M. sold $791.5K2026-04-01 · Evans John M. sold $739.3K2026-01-30 · Evans John M. sold $624.6K2026-10-16 · Evans John M. sold $599.6K2026-10-15 · Evans John M. sold $589.1K2026-03-31 · Evans John M. sold $569.0K2026-03-30 · Evans John M. sold $559.2K2026-01-15 · Bellon Christine sold $554.1K2026-01-29 · Evans John M. sold $476.8K2026-06-29 · Evans John M. sold $471.5K2026-07-27 · Simon Amy sold $429.0K2026-06-29 · Evans John M. sold $415.8K2026-04-01 · Ciaramella Giuseppe sold $290.3K2026-01-29 · Evans John M. sold $257.8K2026-01-22 · Cavanagh Bethany J sold $216.9K2025-12-31 · Emany Sravan Kumar sold $170.6K2026-04-01 · Simon Amy sold $164.7K2026-04-01 · Bellon Christine sold $146.4K2026-01-20 · Cavanagh Bethany J sold $91.4K2026-01-30 · Evans John M. sold $84.3K2026-04-01 · Cavanagh Bethany J sold $79.7K2026-01-15 · Bellon Christine sold $71.0K2026-06-30 · Evans John M. sold $66.2K2026-01-22 · Bellon Christine sold $46.6K2025-12-31 · Bellon Christine sold $34.0K2026-01-15 · Bellon Christine sold $19.8K2026-06-30 · Simon Amy sold $13.0K2025-10-27 · FMR LLC sold $12.2K2026-10-01 · Cavanagh Bethany J sold $4.6K2026-10-16 · JOHN M EVANS filed to sell $599.6K2026-10-15 · JOHN M EVANS filed to sell $589.1K2026-07-27 · AMY SIMON filed to sell $429.3K2026-06-30 · JOHN M EVANS filed to sell $857.7K2026-06-29 · JOHN M EVANS filed to sell $887.4K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BEAM: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
12,609,002 sh
$432.7M
FARALLON CAPITAL MANAGEMENT, L.L.C.
10,236,396 sh
$351.3M
ARK Investment Management LLC
10,234,862 sh
$351.3M
BlackRock, Inc.
8,997,542 sh
$308.8M
STATE STREET CORP
5,827,122 sh
$200.0M

Congress trades in BEAM

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BEAM planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
JOHN M EVANS
Filed 2026-10-16
$599.6K
JOHN M EVANS
Filed 2026-10-15
$589.1K
AMY SIMON
Filed 2026-07-27
$429.3K
JOHN M EVANS
Filed 2026-06-30
$857.7K
JOHN M EVANS
Filed 2026-06-29
$887.4K

BEAM mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ARK Genomic Revolution ETF
$58.8M position · as of 2026-07-31
3.8%
American Beacon ARK Transformational Innovation Fund
$5.3M position · as of 2026-06-30
3.3%
Global X Genomics & Biotechnology ETF
$1.7M position · as of 2026-05-31
3.1%
ARK Innovation ETF
$155.1M position · as of 2026-07-31
2.8%
Horizon Kinetics Medical ETF
$287.9K position · as of 2026-06-30
1.5%
Select Pharmaceuticals Portfolio
$16.5M position · as of 2026-05-31
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 6 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
1 active
1
Not applicable
1 active
4
Multi-phase
4 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$5.8M
$8.4M
$2.3M
-66%
+25%
2024
$6.4M
$7.3M
$3.2M
+32%
+25%
2023
$6.3M
$2.8M
$2.5M
+45%
+26%
2022
$9.5M
-$13.9M
$3.1M
+109%
+20%
2021
$13.9M
$17.0M
$4.7M
+325%
+34%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $13.4M sold by insiders over 180 days, 153 funds added last quarter, $1.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

BEAM financials

Revenue growth
+120.0%
XBRL, annual
Net margin
-57.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$156.0M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Free cash flow, TTM
-$372.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.09x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-3.58x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on assets
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-30.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$2.5B
market value at close 2026-10-27 on 2026-07-28 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-14.5%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$139.7M$63.5M$377.7M$60.9M
Operating income-$383.7M-$415.6M-$176.5M-$338.5M
Net income-$80.0M-$376.7M-$132.5M-$289.1M
EPS (diluted)-0.81-4.58-1.72-4.13
Operating cash flow-$345.1M-$347.2M-$149.2M$22.5M
Cash$294.9M$282.0M$435.9M$232.8M
SEC XBRL, fiscal years, as known on 2026-10-28

BEAM Stock Sonar score 5/7 axes

Find similar shapesCompare

BEAM ranks highest on growth (86th percentile) and institutional and government (53rd), and lowest on insider conviction (6th), among Pharma & Biotech peers.

HealthGrowthInsidersInstitutionsRisk
Financial health
45
Inputs
  • Debt to equity0.09x · 55 pct, sector of 352
  • Cash flow to debt-3.58x · 34 pct, sector of 371
Growth
86
Inputs
  • Revenue growth, YoY+120.0% · 86 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
6
Inputs
  • Net Form 4 buying (codes P and S), 180d-$12.2M · 13 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
53
Inputs
  • Funds adding, latest quarter153 · 83 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$112K · 23 pct, sector of 133
Risk and compliance
39
Inputs
  • Short interest, % of float+31.2% · 4 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+6.6% · 75 pct, sector of 511
2 not measured: Profitability, US patents
  • Profitability needs 2 of 4 inputs, 1 present: tax provision or pre-tax income not filed for the four quarters; the filed year and its quarters do not reconcile, so the trailing figure is withheld
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

BEAM filings, in plain words

Are Beam Therapeutics insiders buying or selling BEAM?

In the 180 days to 2026-10-28, Beam Therapeutics insiders were net sellers, a net $13.4M across purchases and sales reported on Form 4, by 4 sellers.

Are there planned insider sales of BEAM?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.2M of stock; the latest, by JOHN M EVANS, was filed 2026-10-16.

Read the full summary

In the 180 days to 2026-10-28, Beam Therapeutics insiders were net sellers of BEAM, a net $13.4M across purchases and sales reported on Form 4 by 4 sellers. Most of that figure, $10.0M, came from a holder of 10% or more rather than an officer or director. 27% of the 11 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies